Detecting neurodegenerative pathology before overt clinical symptoms emerge represents a major milestone in modern dementia care. Recently, blood-based biomarkers have transformed diagnostic neurology by providing accessible, minimally invasive tools to evaluate Alzheimer disease pathology. However, clinicians often face uncertainty regarding how longitudinal fluctuations in these peripheral markers reflect actual brain tissue loss over time. Understanding this dynamic relationship helps physicians identify individuals at elevated risk of accelerated neurodegeneration before irreversible structural damage occurs.

Understanding Blood-Based Biomarkers in Preclinical Disease

For decades, clinicians relied on cerebrospinal fluid assays and positron emission tomography to identify neurodegeneration. Although these modalities offer high diagnostic accuracy, procedural invasiveness and elevated costs frequently restrict their widespread application. Consequently, investigators developed sensitive assays using single-molecule array technology to detect minute concentrations of circulating brain proteins. Today, blood-based biomarkers provide unprecedented opportunities to screen at-risk individuals in outpatient settings.

In this context, specific plasma proteins reflect distinct neuropathological cascades occurring within the central nervous system. The amyloid-beta ratio reflects parenchymal plaque accumulation, whereas phosphorylated tau measures neurofibrillary tangle pathology. Meanwhile, glial fibrillary acidic protein marks reactive astrogliosis, and neurofilament light indicates ongoing axonal injury. Therefore, examining these diverse proteins longitudinally allows physicians to track how cellular stress transforms into macroscopic structural damage. Furthermore, evaluating cognitively unimpaired individuals with subjective cognitive decline offers a vital window for preventative intervention. Because brain atrophy precedes clinical dementia by years, clinicians need objective peripheral indicators that mirror progressive tissue loss. Thus, defining biomarker trajectories addresses an urgent diagnostic priority.

Cohort Characteristics and Neuroimaging Methodology

To clarify these associations, researchers at the Amsterdam University Medical Centers conducted a prospective observational investigation within the Subjective Cognitive Impairment Cohort. The study team recruited 167 individuals presenting with subjective cognitive decline from a specialized memory clinic. Among these participants, 49 individuals demonstrated baseline amyloid positivity, whereas 118 individuals were amyloid-negative. Notably, amyloid-positive participants were older, with a mean age of 66 years, and included a higher proportion of females compared to the amyloid-negative group.

Over a median follow-up period of five years, participants underwent biennial blood sampling and high-resolution structural magnetic resonance imaging. In total, the study collected 484 serial plasma samples and 457 volumetric scans. The laboratory quantified four core blood markers on the SIMOA platform, ensuring ultra-sensitive measurement across all timepoints. Concurrently, neuroradiologists applied automated segmentation pipelines to quantify volumetric changes across eleven predefined regions of interest. Specifically, the imaging protocol examined five temporal, four parietal, and two frontal regions commonly vulnerable to Alzheimer pathology. The investigators then used linear mixed models to analyze relationships between biomarker trajectories and brain atrophy rates. Consequently, this multi-time-point framework provided exceptional statistical precision.

Distinct Associations of GFAP and pTau217 With Atrophy

The investigation revealed striking differences in how individual plasma biomarkers correlate with neurodegenerative changes across the brain. Most prominently, baseline concentrations and longitudinal increases in glial fibrillary acidic protein showed strong associations with accelerated volume loss across nearly all evaluated cortical regions. Elevated GFAP predicted progressive tissue loss in temporal lobes and throughout parietal and frontal cortices. Therefore, reactive astrogliosis represents a widespread pathological process that closely parallels generalized neurodegeneration.

In contrast, phosphorylated tau demonstrated an anatomically focused pattern of association. Higher baseline pTau217 concentrations correlated specifically with increased atrophy rates across medial temporal structures, including the hippocampus and entorhinal cortex. Furthermore, longitudinal increases in pTau217 tracked progressive volume reductions primarily within these same temporal regions. However, this association reached trend-level significance after false discovery rate correction, suggesting that tau-mediated structural loss accelerates during defined disease intervals. Meanwhile, baseline neurofilament light levels correlated with atrophy across selected temporal structures, but longitudinal increases did not predict accelerated shrinkage. Similarly, the amyloid ratio showed only modest associations with hippocampal volume that did not survive multi-comparison adjustments. Consequently, GFAP and pTau217 emerged as the most clinically informative markers.

Temporal Dynamics Preceding Structural Brain Loss

Understanding the exact timeline connecting molecular biomarker shifts to macroscopic structural damage is critical for clinical decision-making. In an exploratory trajectory analysis, the researchers modeled long-term biomarker curves against progressive hippocampal volume loss. Their modeling demonstrated that peripheral increases in pTau217 occur substantially before detectable macroscopic hippocampal atrophy takes place. Consequently, this temporal gap highlights a valuable therapeutic window during which neuroprotective interventions might prevent irreversible tissue loss.

Moreover, these temporal findings clarify why clinicians often detect elevated blood markers in individuals who still maintain normal volumetric MRI scans. Because fluid biomarkers capture active biochemical cascades at the cellular level, they alter long before gross morphological changes manifest radiologically. Therefore, relying solely on anatomical brain imaging might delay early risk stratification in memory clinics. Additionally, the widespread association between GFAP and neocortical atrophy emphasizes the active participation of neuroinflammation throughout disease progression. Rather than functioning as a passive bystander, astrocytic activation tracks continuous neurodegenerative damage across multiple cerebral lobes. Thus, monitoring both astrocytic activation and tau phosphorylation provides complementary information regarding disease activity and impending structural decline. Clinicians can leverage these distinctive temporal patterns to personalize patient counseling and surveillance protocols.

Clinical Translation and Future Practice Implications

These findings carry profound practical implications for physicians managing patients with subjective memory complaints. In primary care and memory clinics, patients frequently express genuine distress despite scoring normally on standard bedside cognitive tests. When clinicians encounter subjective cognitive decline, peripheral biomarker testing can provide objective reassurance or establish the need for vigilant surveillance. Specifically, obtaining baseline pTau217 and GFAP levels helps stratify patients into low-risk and high-risk trajectories.

Furthermore, integrating blood tests into routine workups could optimize the judicious utilization of costly neuroimaging resources. Instead of ordering serial high-resolution MRIs for every concerned patient, clinicians can reserve detailed structural imaging for individuals exhibiting rising biomarker concentrations. This staged approach reduces healthcare expenditures while preserving diagnostic accuracy in high-volume clinical settings. Importantly, emerging disease-modifying therapies demand precise patient selection during the earliest stages of amyloid and tau accumulation. Because clinical trials show superior efficacy when treatment begins before extensive neuronal loss, early peripheral screening becomes vital. Consequently, longitudinal biomarker tracking enables timely referral to specialist centers where disease-modifying infusions remain viable options. Thus, fluid biomarkers will soon form the cornerstone of proactive dementia prevention strategies.

How do blood-based biomarkers predict regional brain atrophy in Alzheimer disease?

Blood-based biomarkers reflect distinct cellular pathologies occurring within brain tissue. Elevated pTau217 primarily indicates accelerated atrophy in medial temporal structures, including the hippocampus. Meanwhile, increased GFAP reflects reactive astrogliosis, predicting widespread cortical volume loss across temporal, parietal, and frontal lobes before cognitive impairment becomes clinically apparent.

Why is GFAP strongly linked to widespread brain volume loss?

Glial fibrillary acidic protein serves as an established plasma indicator of reactive astrocytic activation. Because neuroinflammation and astrogliosis spread broadly throughout the cerebral cortex during preclinical Alzheimer progression, rising GFAP concentrations track generalized neurodegenerative damage across multiple brain regions rather than remaining confined to isolated memory circuits.

Can blood tests replace magnetic resonance imaging in memory evaluations?

Blood tests cannot completely replace structural magnetic resonance imaging in current clinical workflows. Although peripheral biomarkers reliably identify underlying amyloid and tau pathology, MRI scans remain indispensable for excluding alternative intracranial etiologies, assessing vascular white matter lesions, and evaluating baseline anatomical volume loss before initiating specialized treatments.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. Trieu C et al. Longitudinal Change in Blood-Based Biomarkers and the Association With MRI-Measured Neurodegeneration in Cognitively Unimpaired Individuals. Neurology. 2026 Jun 23. doi: 10.1212/WNL.0000000000218119. PMID: 42224636.
2. Verberk IMW, Laarhuis BI, van den Bosch KA, et al. Longitudinal Blood-Based Biomarkers and Clinical Progression in Subjective Cognitive Decline. JAMA Netw Open. 2025;8(12):e2545862.
3. Del Campo M, Belomo G, Teunissen CE, et al. New blood biomarkers enable differentiation between the main neurodegenerative diseases that cause dementia. Nat Aging. 2026;6(7):1102-1115.